Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023 07:50 ET
|
Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
September 21, 2023 08:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Reports Second Quarter 2023 Financial Results
August 22, 2023 09:29 ET
|
Purple Biotech Ltd.
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023 08:15 ET
|
Purple Biotech Ltd.
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2...
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
May 16, 2023 16:00 ET
|
Purple Biotech Ltd.
Expands pipeline with acquisition of new tri-specific antibodiesData readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....
Purple Biotech Debuts Scientific Advisory Board
April 25, 2023 08:00 ET
|
Purple Biotech Ltd.
Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE...
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
April 19, 2023 08:15 ET
|
Purple Biotech Ltd.
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
April 18, 2023 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,...
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
March 24, 2023 07:00 ET
|
Purple Biotech Ltd.
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 ...
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
March 16, 2023 07:00 ET
|
Purple Biotech Ltd.
Reduction in neutrophil extracellular traps (NETs) markersPotential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- ...